Literature DB >> 33139490

Zika Virus-Infected Decidual Cells Elicit a Gestational Age-Dependent Innate Immune Response and Exaggerate Trophoblast Zika Permissiveness: Implication for Vertical Transmission.

Ozlem Guzeloglu-Kayisli1, Xiaofang Guo2, Zhonghua Tang3, Nihan Semerci2, Asli Ozmen2, Kellie Larsen2, Duygu Mutluay2, Seth Guller3, Frederick Schatz2, Umit Ali Kayisli2, Charles Joseph Lockwood1.   

Abstract

Vertical transmission of the Zika virus (ZIKV) causes severe fetal defects, but the exact pathogenic mechanism is unclear. We identified up to a 10,480-fold higher expression of viral attachment factors AXL, GAS6, and PROS1 and a 3880-fold increase in ZIKV infectiousness/propagation in human term decidual stromal cells versus trophoblasts. Moreover, levels of viral attachment factors and ZIKV are significantly increased, whereas expression of innate immune response genes are significantly decreased, in human first trimester versus term decidual cells. ZIKV-infected decidual cell supernatants increased cytotrophoblasts infection up to 252-fold compared with directly infected cytotrophoblasts. Tizoxanide treatment efficiently inhibited Zika infection in both maternal and fetal cells. We conclude that ZIKV permissiveness, as well as innate immune responsiveness of human decidual cells, are gestational age dependent, and decidual cells augment ZIKV infection of primary human cytotrophoblast cultures, which are otherwise ZIKV resistant. Human decidual cells may act as reservoirs for trimester-dependent placental transmission of ZIKV, accounting for the higher Zika infection susceptibility and more severe fetal sequelae observed in early versus late pregnancy. Moreover, tizoxanide is a promising agent in preventing perinatal Zika transmission as well as other RNA viruses such as coronavirus.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2020        PMID: 33139490     DOI: 10.4049/jimmunol.2000713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Preeclampsia is Associated With Reduced ISG15 Levels Impairing Extravillous Trophoblast Invasion.

Authors:  Asli Ozmen; Ozlem Guzeloglu-Kayisli; Selcuk Tabak; Xiaofang Guo; Nihan Semerci; Chinedu Nwabuobi; Kellie Larsen; Ali Wells; Asli Uyar; Sefa Arlier; Ishani Wickramage; Hasan Alhasan; Hana Totary-Jain; Frederick Schatz; Anthony O Odibo; Charles J Lockwood; Umit A Kayisli
Journal:  Front Cell Dev Biol       Date:  2022-06-28

2.  Regulation of Proinflammatory Molecules and Tissue Factor by SARS-CoV-2 Spike Protein in Human Placental Cells: Implications for SARS-CoV-2 Pathogenesis in Pregnant Women.

Authors:  Xiaofang Guo; Nihan Semerci; Viviana De Assis; Umit A Kayisli; Frederick Schatz; Thora S Steffensen; Ozlem Guzeloglu-Kayisli; Charles J Lockwood
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 3.  Infections at the maternal-fetal interface: an overview of pathogenesis and defence.

Authors:  Christina J Megli; Carolyn B Coyne
Journal:  Nat Rev Microbiol       Date:  2021-08-25       Impact factor: 60.633

4.  Interferon Lambda Signals in Maternal Tissues to Exert Protective and Pathogenic Effects in a Gestational Stage-Dependent Manner.

Authors:  Rebecca L Casazza; Drake T Philip; Helen M Lazear
Journal:  mBio       Date:  2022-04-26       Impact factor: 7.786

5.  Innate immune signaling in trophoblast and decidua organoids defines differential antiviral defenses at the maternal-fetal interface.

Authors:  Liheng Yang; Eleanor C Semmes; Cristian Ovies; Christina Megli; Sallie Permar; Jennifer B Gilner; Carolyn B Coyne
Journal:  Elife       Date:  2022-08-17       Impact factor: 8.713

6.  Usutu Virus Infects Human Placental Explants and Induces Congenital Defects in Mice.

Authors:  Hélène Martin; Jonathan Barthelemy; Yamileth Chin; Mathilde Bergamelli; Nathalie Moinard; Géraldine Cartron; Yann Tanguy Le Gac; Cécile E Malnou; Yannick Simonin
Journal:  Viruses       Date:  2022-07-25       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.